Processa Pharmaceuticals, Inc. Interest Expense on Debt
Processa Pharmaceuticals, Inc. (PCSA) reported Interest Expense on Debt of $59.06 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-16.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebt · last filed 2018-04-16
- Processa Pharmaceuticals, Inc. interest expense, debt for fiscal 2017 was $59.06K.
| Period end | Interest Expense, Debt 12 month |
|---|---|
| 2017-12-31 | $59.06K 10-K · filed 2018-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |